Balaji Amines Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported consolidated revenue of ₹472 crore and EBITDA of ₹106 crore for Q2 FY27. Net profit for the quarter stood at ₹67 crore. The company also highlighted significant progress in its expansion pipeline, including the commissioned Acetonitrile (ACN) facility and the upcoming N-Methyl Morpholine (NMM) commercialization.
Balaji Amines Announces Q2 FY27 Financial Results
Balaji Amines Limited, a prominent manufacturer of Aliphatic Amines and Speciality Chemicals, has declared its unaudited financial results for the second quarter and half-year ended September 30, 2026. The consolidated figures reveal a robust performance with a total revenue of ₹472 crore for the quarter, marking a substantial increase from ₹348 crore in the corresponding quarter of the previous fiscal year (Q2 FY26).
Key Financial Highlights (Consolidated)
The company reported a consolidated EBITDA of ₹106 crore for Q2 FY27, compared to ₹67 crore in Q2 FY26. The EBITDA margin stood at 22%. Profit After Tax (PAT) for the quarter was ₹67 crore, a notable increase from ₹37 crore in Q2 FY26. Diluted Earnings Per Share (EPS) was reported at ₹20.76 for the quarter.
For the half-year ended September 30, 2026 (H1 FY27), consolidated revenue reached ₹933 crore, with EBITDA at ₹227 crore and PAT at ₹146 crore.
Operational Performance and Sales Volumes
Consolidated sales volumes for Q2 FY27 were 24,491 MT, against 26,165 MT in Q2 FY26. The breakdown for Q2 FY27 includes 6,525 MT of Amines, 8,974 MT of Amines Derivatives, and 8,992 MT of Specialty Chemicals. The company stated that volumes were maintained at similar levels, supported by stable commodity prices and consistent demand.
Growth Drivers and Expansion Pipeline
Balaji Amines continues to focus on capacity expansion, import substitution, and value-added specialty chemicals. Key developments include:
- Commercial production commenced at the expanded Acetonitrile (ACN) facility, increasing capacity to 1,440 TPM.
- Successful commissioning of the 100,000 TPA Dimethyl Ether (DME) plant, positioning the company in the import substitution market.
- The next product planned for commercialization is N-Methyl Morpholine (NMM).
- Expansion programs for high-value specialty chemicals at Unit-I and Unit-II are progressing as planned, with Unit-II (Chincholi) targeted for commissioning in Q4 FY27.
The company highlighted its standalone operations as a zero-debt company. Management expressed confidence in driving sustainable growth and creating long-term shareholder value through its strengthened product mix and expansion roadmap.
Source: BSE
